| Literature DB >> 25108400 |
Jiajing Liu, Bo Xie, Shuilian Chen, Feng Jiang, Wei Meng.
Abstract
BACKGROUND: Inflammation is a response of body tissues to injury or irritation. Small RNAs, such as miR-146a and miR-499, participate in various processes of tumorigenesis. A recent study indicates that inflammation and abnormal immune responses may promote malignant progression in cancer development, indicating that inflammation-related polymorphisms such as miR-146a rs2910164 and miR-499 rs3746444 are crucial. However, studies on the association of these two polymorphisms with hepatocellular carcinoma (HCC) are inconclusive and inconsistent. We aimed at accessing the combined result of reported studies and make a more precise estimate of the relationship.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25108400 PMCID: PMC4236519 DOI: 10.1186/s12881-014-0092-7
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Figure 1Flow diagram of study identification.
Characteristics of studies included in the meta-analysis
| Zhou | 2011 | China | 669(186/483) | PCR-RFLP | 33 | 86 | 67 | 71 | 254 | 158 | 3.658195 | 0.055794 |
| Yu | 2012 | China | 200(100/100) | PCR-RFLP | 27 | 45 | 28 | 21 | 46 | 33 | 0.443003 | 0.505677 |
| Xu | 2008 | China | 983(479/504) | PCR-RFLP | 80 | 241 | 158 | 58 | 249 | 197 | 2.430179 | 0.119019 |
| Wang-1 | 2011 | China(Jiangsu) | 1722(640/1082) | MASSARRAY | 122 | 330 | 188 | 166 | 551 | 365 | 3.171700 | 0.074924 |
| Wang-2 | 2011 | China(Henan) | 583(199/384) | MASSARRAY | 38 | 103 | 58 | 61 | 185 | 138 | 0.005863 | 0.938967 |
| Wang-3 | 2011 | China(Shanghai) | 680(277/403) | MASSARRAY | 52 | 128 | 97 | 45 | 188 | 170 | 0.420956 | 0.51646 |
| Li | 2012 | China | 1120(560/560) | AS-PCR | 124 | 302 | 134 | 92 | 288 | 180 | 1.670302 | 0.196218 |
| Zhang | 2011 | China | 1765(925/840) | PIRA-PCR | 156 | 450 | 319 | 151 | 386 | 303 | 2.086630 | 0.148594 |
| Kim | 2012 | Korean | 360(159/201) | PCR-RFLP | 14 | 88 | 57 | 24 | 103 | 74 | 1.71898 | 0.189825 |
| Akkiz | 2011 | Turkey | 444(222/222) | PCR-RFLP | 137 | 75 | 10 | 144 | 67 | 11 | 0.758665 | 0.383747 |
For miR-146a rs2910164.
Characteristics of studies included in the meta-analysis
| Kim | 2012 | Korean | 399(198/201) | PCR-RFLP | 3 | 86 | 109 | 7 | 74 | 120 | 1.178699 | 0.277621 |
| Yu | 2012 | China | 205(105/100) | PCR-RFLP | 24 | 45 | 36 | 10 | 36 | 54 | 1.147959 | 0.283977 |
| Zhou | 2011 | China | 716(233/483) | PCR-RFLP | 4 | 88 | 141 | 12 | 100 | 371 | 2.701215 | 0.100272 |
| Akkiz | 2011 | Turkey | 432(210/222) | PCR-RFLP | 90 | 75 | 45 | 82 | 93 | 47 | 4.401451 | 0.055908 |
For miR-499 rs3746444.
Meta-analysis of the miR-146a rs2910164 polymorphisms and HCC risk
| G v C | 1.153 | 1.083-1.228 | <0.001 | F | 39.9% | 0.091 | 0.816 |
| GC v CC | 1.165 | 1.054-1.286 | 0.003 | F | 0.0% | 0.690 | 0.874 |
| GG v CC | 1.361 | 1.192-1.553 | <0.001 | F | 43.2% | 0.070 | 0.990 |
| GG/GC v CC | 1.213 | 1.104-1.333 | <0.001 | F | 6.7% | 0.380 | 0.927 |
| GG v GC/CC | 1.210 | 1.080 -1.356 | 0.001 | F | 46.1% | 0.054 | 0.846 |
(F: Fixed-effects model).
Figure 2Forest plots under additive model of study between the miR-146a rs2910164 polymorphism and HCC risk.
Subgroup-analysis of the miR-146a rs2910164 polymorphisms and HCC risk
| | | | | | | | |
| Chinese | 8 | 1.174 | 1.099-1.253 | <0.001 | F | 38.5% | 0.123 |
| Other | 2 | 0.939 | 0.752-1.172 | 0.577 | F | 0.0% | 0.875 |
| | | | | | | | |
| PCR-RFLP | 5 | 1.103 | 0.982-1.239 | 0.097 | F | 25.8% | 0.249 |
| Other | 5 | 1.174 | 1.090-1.265 | <0.001 | F | 54.6% | 0.066 |
| | | | | | | | |
| <700 | 6 | 1.129 | 1.010-1.262 | 0.033 | F | 31.3% | 0.201 |
| >700 | 4 | 1.164 | 1.079-1.256 | <0.001 | F | 60.0% | 0.057 |
Meta-analysis of the miR-499 rs3746444 polymorphisms and HCC risk
| C v T | 1.118 | 0.773-1.616 | 0.554 | R | 77.6% | 0.004 | 0.33 |
| CT v TT | 0.994 | 0.784-1.262 | 0.963 | F | 42.5% | 0.156 | 0.382 |
| CC v TT | 1.266 | 0.596-2.687 | 0.540 | R | 63.8% | 0.040 | 0.827 |
| CC/CT v TT | 1.091 | 0.726-1.641 | 0.674 | R | 68.2% | 0.024 | 0.292 |
| CC v CT/TT | 1.265 | 0.924 -1.732 | 0.143 | F | 50.8% | 0.107 | 0.884 |
(F: Fixed-effects model, R: Random-effects model).
Subgroup-analysis of the miR-499 rs3746444 polymorphisms and HCC risk
| | OR | 95% CI | P value | Model | I2 | P value | |
| Chinese | 2 | 1.424 | 0.730-2.776 | 0.300 | R | 83.3% | 0.015 |
| Other | 2 | 0.949 | 0.764-1.179 | 0.636 | F | 69.9% | 0.068 |
| | | | | | | | |
| <300 | 1 | 2.020 | 1.333-3.063 | 0.001 | NA | NA | NA |
| >300 | 3 | 0.968 | 0.804-1.165 | 0.733 | F | 41.8% | 0.179 |
| | OR | 95% CI | P value | Model | I2 | P value | |
| Chinese | 2 | 2.171 | 1.149-4.104 | 0.017 | F | 73.4% | 0.053 |
| Other | 2 | 1.021 | 0.638-1.634 | 0.931 | F | 29.0% | 0.235 |
| | | | | | | | |
| <300 | 1 | 3.600 | 1.539-8.421 | 0.003 | NA | NA | NA |
| >300 | 3 | 0.998 | 0.647-1.541 | 0.994 | F | 41.8% | 0.179 |
| | OR | 95% CI | P value | Model | I2 | P value | |
| Chinese | 2 | 1.325 | 0.962-1.824 | 0.085 | F | 73.1% | 0.054 |
| Other | 2 | 0.838 | 0.611-1.148 | 0.271 | F | 46.2% | 0.173 |
| | | | | | | | |
| <300 | 1 | 2.087 | 1.184-3.679 | 0.011 | NA | NA | NA |
| >300 | 3 | 0.916 | 0.716-1.174 | 0.489 | F | 24.8% | 0.264 |
Sensitive-analysis of the miR-499 rs3746444 polymorphisms and HCC risk
| C v T | 0.968 | 0.804-1.165 | 0.733 | F | 41.8% | 0.179 | 0.414 |
| CT v TT | 0.907 | 0.699-1.176 | 0.462 | F | 2.9% | 0.357 | 0.868 |
| CC v TT | 0.998 | 0.647-1.541 | 0.994 | F | 0.0% | 0.479 | 0.266 |
| CC/CT v TT | 0.916 | 0.716-1.174 | 0.489 | F | 24.8% | 0.264 | 0.836 |
| CC v CT/TT | 1.070 | 0.756-1.514 | 0.704 | F | 0.0% | 0.107 | 0.216 |
(F: Fixed-effects model).